Navigation Links
In Vitro Study of Adamas Pharmaceuticals' Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
Date:9/13/2009

SAN FRANCISCO, Sept. 13 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that a multi-center in vitro study of its proprietary triple combination antiviral drug (TCAD) therapy showed substantially greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double therapy and that the triple combination is active against drug-resistant flu strains. The study was presented during an oral presentation at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

Adamas' TCAD therapy consists of a proprietary fixed-dose combination drug product (amantadine and ribavirin), to be administered adjunctively with a neuraminidase inhibitor such as Tamiflu (oseltamivir phosphate, Roche). In this study, using a scientifically accepted in vitro infection model, researchers compared amantadine, ribavirin, and oseltamivir alone and in combination against influenza A viruses that are resistant to either oseltamivir or amantadine, including novel A/H1N1. The results are the product of scientific collaborations with the United States Naval Health Research Center, San Diego; University of Alabama, Birmingham; Utah State University, Logan, Utah; and the Amsterdam Medical Center in the Netherlands.

"These data suggest that the triple combination of amantadine, ribavirin, and oseltamivir was highly synergistic in its ability to inhibit influenza virus replication, including the current circulating novel H1N1 virus. The triple combination approach, because it strikes multiple targets within the viruses, might also help to prevent the development of new resistance in susceptible flu strains," said study investigator Mark Prichard, Ph.D., Professor in the Department of Pediatrics, University of Alabama at Birmingham. "This triple combination approach may represent a highly activ
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
4. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
5. MatTeks EpiDerm In Vitro Tissues Headed for Validation in Europe
6. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
7. New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria
8. Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 In ... the Canadian International Pharmacy Association (CIPA) ... online from licensed Canadian pharmacies. Approximately 64% of respondents ... medications from a non-U.S. pharmacy due to costs ... not covered under their insurance plan.   ...
(Date:5/27/2015)... , May 27, 2015  Genomic Health, Inc. (Nasdaq: ... Operating Officer and Chief Financial Officer, will present at the ... City on Monday, June 1 at 8:30 a.m. ... subsequently archived webcast of the presentation, go to the  Investor ... .  Please connect to the web site at least 15 ...
(Date:5/27/2015)...  Later this week, Cardinal Health Specialty Solutions ... outcomes research (HEOR) studies that reinforce the importance ... reimbursement strategies.   Dr. Bruce ... of Cardinal Health Specialty Solutions, says that physicians, ... more than a decade that clinical trials alone ...
Breaking Medicine Technology:Canadian International Pharmacy Association (CIPA) Survey of Americans Finds 64% Purchase Medications from Canada Due to Affordability 2Canadian International Pharmacy Association (CIPA) Survey of Americans Finds 64% Purchase Medications from Canada Due to Affordability 3Genomic Health to Present at the Jefferies 2015 Global Healthcare Conference 2Genomic Health to Present at the Jefferies 2015 Global Healthcare Conference 3New Studies Reinforce Important Role Real-World Patient Data Can Play in Developing Value-based Reimbursement Strategies 2New Studies Reinforce Important Role Real-World Patient Data Can Play in Developing Value-based Reimbursement Strategies 3
...  NxStage Medical, Inc. (Nasdaq: NXTM ), a ... to release its financial results for the fourth quarter ... February 29, 2012  before the opening of the financial ... NxStage will also host a conference call at ...
... (OTC BB: IVOB), a medical device company focused on ... that the National Health Surveillance Agency (ANVISA) in Brazil ... a Class II device. This approval allows the INVOcell ... Brazil and marks a major milestone in the history ...
Cached Medicine Technology:NxStage® to Report Fourth Quarter and Full Year 2011 Financial Results 2INVO Bioscience Announces Approval of INVOcell by Brazil's ANVISA 2INVO Bioscience Announces Approval of INVOcell by Brazil's ANVISA 3
(Date:5/27/2015)... This is a professional and ... Omega-3 industry. The report provides a basic overview ... industry chain structure. The Omega-3 market analysis is ... competitive landscape analysis, and key regions development status. ... Company, Seadragon Marine Oils, Norwegian Fish Oil, Croda ...
(Date:5/27/2015)... May 27, 2015 With InnerVoice Communication ... environment where the message is not only heard but seen ... or virtually any motivating image. This award-winning and affordable app ... , Now, using InnerVoice Sender app in ... sent to a learner remotely for no additional cost. , ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 For a limited ... Ghasri, is now offering discounts on facial fillers. Skin loses ... the age of 18. This lost collagen can lead to ... wrinkles and expression lines. Facial fillers are an excellent way ... turn to facial fillers to create a softer and more ...
(Date:5/27/2015)... May 27, 2015 Decorview , ... America, is offering free design advice to homeowners looking ... , “Light pollution caused by streetlights, outdoor signs, ... restless night’s sleep, said Kim Rush, VP of sales ... cities across North America with recently installed LED streetlights– ...
(Date:5/27/2015)... CRN International, the radio marketing and promotions ... Financial Officer. , Prinner most recently was Principal of ... financial/operational executive positions at telecom and technology services companies ... and SNET. His accounting and consulting career began ... will be able to tap into his experience of ...
Breaking Medicine News(10 mins):Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 3Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 4Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Discounts on Facial Fillers 2Health News:Decorview Helps Homeowners Combat Light Pollution 2Health News:CRN International Names New Chief Financial Officer 2
... for years may be embarrassed to let a spouse or partner ... shyness can hamper a couple,s willingness to do total body skin ... melanoma. Melanoma, the most deadly form of skin cancer, can appear ... "I had a woman tell me, ,I don,t want my husband ...
... DE May 20, 2008 A new ... therapy and fluticasone/salmeterol combination therapy, as measured by ... in the study were ages 18 years and ... been previously treated with inhaled corticosteroids.1 Results were ...
... It is not uncommon to find tissue that normally lines ... "heterotopic" gastric tissue has been identified in such diverse locations ... , This case, reported by a team led by Dr. ... edition of the World Journal of Gastroenterology. , Typically, when ...
... than a dose-response effect on mortality from alcohol-related liver ... beverage, was more significant to liver injury. , This ... You-Ming Li from Zhejiang University, is described in a ... in the World Journal of Gastroenterology. , The study ...
... with cirrhosis of the liver develop abnormally dilated blood ... vomiting may occur from the rupture of these varices, ... eradicate these varices. To achieve this, an elastic band ... allows the consecutive application of up to six rubber ...
... and calm, according to a new study from the Population ... at about age 60, participants reported more feelings of ease ... John Mirowsky, professors of sociology, have published the findings in ... issue of Social Science and Medicine. The research was funded ...
Cached Medicine News:Health News:A loving partner can save your skin 2Health News:A loving partner can save your skin 3Health News:Heterotopic gastric tissue simulating acute appendicitis 2Health News:How to save cost for esophageal varices? 2Health News:With age comes a sense of peace and calm 2
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
Medicine Products: